Astragaloside IV reduces diabetic kidney injury by inhibiting the PKC/NOX4/MAPK pathway.
Astragaloside IV 透過抑制 PKC/NOX4/MAPK 訊息傳導路徑減輕糖尿病腎臟損傷
Ren Fail 2025-09-21
Astragaloside IV(AS)能改善糖尿病腎病大鼠的血糖、血脂和腎功能,減少腎臟損傷與纖維化。其主要機制是降低氧化壓力和發炎,抑制 PKC-β/NOX4/MAPK 訊號路徑。這顯示 AS 有機會成為糖尿病腎病的新療法。
相關文章PubMedDOI推理
Accuracy of Identification of Cardiovascular Events with ICD Diagnosis Codes versus Physician Adjudication in CKD and Kidney Failure.
使用 ICD 診斷碼與醫師審核在慢性腎臟病(CKD)及腎衰竭患者中辨識心血管事件的準確性
J Am Soc Nephrol 2025-09-17
Uncovering Chronic Disease Disparities Within Compacts of Free Association Migrant Populations in Hawaii.
揭示夏威夷自由聯合協定(Compacts of Free Association, COFA)移民族群中的慢性疾病差異
Clin J Am Soc Nephrol 2025-09-17
Current epidemiological overview of glomerulonephritis in Latin America: a systematic literature review.
拉丁美洲腎小球腎炎的現行流行病學概況:系統性文獻回顧
J Nephrol 2025-09-16
AI-powered insights in pediatric nephrology: current applications and future opportunities.
兒童腎臟科中 AI 驅動的洞見:現今應用與未來機會
Pediatr Nephrol 2025-09-16
AI 正在改變小兒腎臟科,不只提升診斷和治療的精準度,也讓工作流程更有效率。AI 能分析各種資料,幫助早期發現腎臟問題、預測病情發展,還能優化治療方式,減輕醫護人員行政負擔。不過,資料隱私、演算法偏誤和專業訓練等問題還需要克服。只要妥善運用,AI 有機會讓小兒腎臟醫療更個人化、更有效率。
相關文章PubMedDOI推理
Expression of ADAM17 and serum PTH levels in dialysis patients with and without diabetes: Potential implications for vascular calcification.
洗腎合併及未合併糖尿病患者中 ADAM17 表現及血清 PTH 濃度:對血管鈣化的潛在影響
Nefrologia (Engl Ed) 2025-09-26